These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 25944034)
21. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Shabsigh R; Crawford ED; Nehra A; Slawin KM Int J Impot Res; 2009; 21(1):9-23. PubMed ID: 18633357 [TBL] [Abstract][Full Text] [Related]
22. Testosterone Therapy and Prostate Cancer: Incorporating Low-Level Evidence into Practical Recommendations. Morales A; Siemens DR Urol Clin North Am; 2022 Nov; 49(4):573-582. PubMed ID: 36309414 [TBL] [Abstract][Full Text] [Related]
23. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798 [TBL] [Abstract][Full Text] [Related]
24. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645 [TBL] [Abstract][Full Text] [Related]
25. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. Rhoden EL; Morgentaler A J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413 [TBL] [Abstract][Full Text] [Related]
26. Re: treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. Seftel A J Urol; 2011 Feb; 185(2):635-6. PubMed ID: 22088646 [No Abstract] [Full Text] [Related]
27. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Blick G Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769 [TBL] [Abstract][Full Text] [Related]
28. Diagnosis and Treatment of Testosterone Deficiency: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSMĀ 2015). Khera M; Adaikan G; Buvat J; Carrier S; El-Meliegy A; Hatzimouratidis K; McCullough A; Morgentaler A; Torres LO; Salonia A J Sex Med; 2016 Dec; 13(12):1787-1804. PubMed ID: 27914560 [TBL] [Abstract][Full Text] [Related]
29. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study). Shigehara K; Konaka H; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Iwamoto T; Koh E; Mizokami A; Namiki M Andrologia; 2018 Feb; 50(1):. PubMed ID: 28497534 [TBL] [Abstract][Full Text] [Related]
31. [Hypogonadism and cardiovascular diseases in men]. Ter Arkh; 2011; 83(10):61-7. PubMed ID: 22185029 [TBL] [Abstract][Full Text] [Related]
32. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. Morales A; Black AM; Emerson LE BJU Int; 2009 Jan; 103(1):62-4. PubMed ID: 18671790 [TBL] [Abstract][Full Text] [Related]
33. Effects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism. Meuleman EJ; Legros JJ; Bouloux PM; Johnson-Levonas AO; Kaspers MJ; Elbers JM; Geurts TB; Meehan AG; Aging Male; 2015; 18(3):157-63. PubMed ID: 26030346 [TBL] [Abstract][Full Text] [Related]
34. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. Kaufman JM; Graydon RJ J Urol; 2004 Sep; 172(3):920-2. PubMed ID: 15310998 [TBL] [Abstract][Full Text] [Related]
35. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer. Meza J; Weaver K; Martin S Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582 [No Abstract] [Full Text] [Related]
36. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Francomano D; Ilacqua A; Bruzziches R; Lenzi A; Aversa A Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347 [TBL] [Abstract][Full Text] [Related]
37. Clinical use of androgens. Snyder PJ Annu Rev Med; 1984; 35():207-17. PubMed ID: 6372655 [TBL] [Abstract][Full Text] [Related]
38. Sleep disturbance as a clinical sign for severe hypogonadism: efficacy of testosterone replacement therapy on sleep disturbance among hypogonadal men without obstructive sleep apnea. Shigehara K; Konaka H; Sugimoto K; Nohara T; Izumi K; Kadono Y; Namiki M; Mizokami A Aging Male; 2018 Jun; 21(2):99-105. PubMed ID: 28920756 [TBL] [Abstract][Full Text] [Related]
39. Prostate cancer: Testosterone therapy for hypogonadal men with prostate cancer. Catarinicchia SP; Crawford ED Nat Rev Urol; 2016 Sep; 13(9):497-8. PubMed ID: 27431338 [No Abstract] [Full Text] [Related]
40. Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement. El-Sakka AI; Hassoba HM; Elbakry AM; Hassan HA J Sex Med; 2005 Mar; 2(2):235-40. PubMed ID: 16422891 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]